Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

British Journal of Cancer

Volumn 111, Issue 9, 2014, Pages 1802-1809

  Mahon, K L ^a,b,c   Qu, W ^b   Devaney, J ^b   Paul, C ^b   Castillo, L ^b   Wykes, R J ^d   Chatfield, M D ^e   Boyer, M J ^a,c,d   Stockler, M R ^a,c,f   Marx, G ^c,g   Gurney, H ^c,h   Mallesara, G ⁱ   Molloy, P L ^j   Horvath, L G ^a,b,c,d   Clark, S J ^b,k  

^a Chris O'Brien Lifehouse   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Northern Haematology and Oncology Group SAN Clinic   (Australia)

^h WESTMEAD HOSPITAL   (Australia)

ⁱ CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^j CSIRO   (Australia)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

castrate resistant prostate cancer; chemotherapy; glutathione S transferase 1; methylation; prognosis; therapeutic response

Indexed keywords

CABAZITAXEL; DNA; DOCETAXEL; GLUTATHIONE TRANSFERASE; METHYLATED GLUTATHIONE S TRANSFERASE 1; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; FOLLOW UP; GENETIC MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SURVIVAL PREDICTION; TREATMENT RESPONSE; VALIDATION STUDY; BLOOD; CANCER STAGING; CPG ISLAND; DNA METHYLATION; DRUG EFFECTS; EPIGENETICS; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROMOTER REGION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TUMOR EMBOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; EPIGENOMICS; FOLLOW-UP STUDIES; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 84908548256     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.463     Document Type: Article

References (30)

1. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25: 3965-3970.
2. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostatespecific antigen recurrence following radical prostatectomy. Clin Cancer Res 11: 4037-4043.
3. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, Vlassov VV, Laktionov PP (2008) Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci 1137: 222-225.
4. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, Chow NH, Grasso M, Wu L, Westra WB, Sidransky D (2001) Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 7: 2727-2730.
5. Danila DC, Fleisher M, Scher HI (2011) Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17: 3903-3912.
6. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI (2007a) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13: 7053-7058.
7. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI (2007b) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13: 7053-7058.
8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376: 1147-1154.
9. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-6309.
10. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, Miller K (2000) Fluorescent methylation-specific polymerase chain reaction for DNAbased detection of prostate cancer in bodily fluids. Cancer Res 60: 5941-5945.
11. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG (2003) Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clinical Cancer Res 9: 2673-2677.
12. Hayes JD, Pulford DJ (1995) The glutathione S-Transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600.
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer Statistics, 2009. CA Cancer J Clin 59: 225-249.
14. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF (2011) Epigenetics in prostate cancer: Biologic and clinical relevance. Eur Urol 60: 753-766.
15. Jeronimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, Sidransky D (2002) Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60: 1131-1135.
16. Kantoff PW,HiganoCS, ShoreND, Berger ER, Small EJ, PensonDF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, FrohlichMW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
17. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-Transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91: 11733-11737.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391.
19. Millar DM, Ow K, Paul C, Russell P, Molloy P, Clark SJ (1999) Detailed methylation analysis of the glutathione S-Transferase pi (GSTP1) gene in prostate cancer. Oncogene 18: 1313-1324.
20. Okegawa T, Nutahara K, Higashihara E (2010) Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol 17: 466-475.
21. PetrylakDP, Tangen CM,HussainMH, Lara PNJ, Jones JA, TaplinME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
22. Rand K, Qu W, Ho T, Clark S, Molloy P (2002) A Companion to Methods in Enzymology Methods 27: 114-120.
23. Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N, Elandt K, Krainer M (2007) Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 67: 427-432.
24. Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, Rozet F, Cathelineau X, Vallancien G, Hamdy FC, Cussenot O (2007) Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 13: 1720-1725.
25. Rushmore TH, Pickett CB (1993) Glutathione S-Transferases, structure, regulation, and therapeutic implications. J Biol Chem 268: 11475-11478.
26. Ruzza P, Rosato A, Rossi CR, Floreani M, Quintieri L (2009) Glutathione transferases as targets for cancer therapy. Anticancer Agents Med Chem 9: 763-777.
27. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G (2009a) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 10: 233-239.
28. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G (2009b) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 10: 233-239.
29. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
30. Thompson IM, Ankerst DP, Tangen CM (eds) (2009) Current Clinical Urology: Prostate Cancer Screening. Humana Press: Totowa, NJ, USA.